ArticleJournal of prevention (2022)2026
Depressive Symptom Trajectories and Incident Pain: The Role of Nocturnal Sleep Duration in Two Prospective Cohort Studies.
Article in Journal of prevention (2022), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study aims to investigate the mediating role of nocturnal sleep duration in the association between depressive symptoms trajectories and subsequent pain outcomes. Using data from the English Longitudinal Study of Ageing (ELSA) and the China Health and Retirement Longitudinal Study (CHARLS), 6,874 participants were included. Latent class mixture models (LCMM) were employed to identify depressive symptoms trajectories. Logistic regression analysis was conducted to examine the association between these trajectories and pain. Three depressive symptoms trajectories were identified in both cohorts: low-stable (class 1), increase-then-decrease (class 2), and decrease-then-increase (class 3). In ELSA, classes 2 and 3 exhibited 93% (OR = 1.93, 95% CI: 1.47, 2.52) and 51% (OR = 1.51, 95% CI: 1.20, 1.88) increases in pain risk, respectively. In CHARLS, class 2 exhibited a 183% (OR = 2.83, 95% CI: 2.32, 3.47) and class 3 a 173% (OR = 2.73, 95% CI: 2.29, 3.26) increase in pain risk. In ELSA, nocturnal sleep duration explained 5.97% (95% CI: 0.0081, 0.1460) of the association between class 2 and pain onset, and 6.07% (95% CI: 0.0080, 0.1811) for class 3. In CHARLS, the mediation proportions were 4.44% (95% CI: 0.0019, 0.0915) for class 2 and 2.74% (95% CI: 0.0022, 0.0558) for class 3. Different trajectories of depressive symptoms are associated with varying pain risks, a relationship partially mediated through sleep. These findings underscore the necessity of ongoing management of depressive symptoms and sleep conditions for pain prevention.
Indexed as
Identifiers
42566188What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.